Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase of approximately 347% compared to the typical volume of 650 call options.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wedbush restated an “outperform” rating and set a $21.00 price target on shares of Immunome in a research note on Friday, November 7th. Evercore ISI started coverage on Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 target price on the stock. Craig Hallum initiated coverage on Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Leerink Partners set a $40.00 price objective on Immunome in a report on Monday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus price target of $26.36.

Institutional Trading of Immunome

A number of hedge funds have recently made changes to their positions in the stock. MetLife Investment Management LLC boosted its position in Immunome by 19.1% during the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after buying an additional 6,792 shares during the period. Tema Etfs LLC purchased a new position in shares of Immunome in the second quarter valued at about $1,074,000. Kennedy Capital Management LLC raised its stake in shares of Immunome by 642.6% during the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock valued at $1,017,000 after acquiring an additional 94,627 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Immunome by 55.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock worth $5,216,000 after purchasing an additional 275,000 shares during the period. Finally, Intech Investment Management LLC grew its stake in shares of Immunome by 17.8% in the second quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock worth $377,000 after purchasing an additional 6,141 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Trading Up 15.7%

Shares of NASDAQ IMNM opened at $22.64 on Tuesday. Immunome has a 12 month low of $5.15 and a 12 month high of $25.30. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.67 and a beta of 2.17. The business has a 50-day moving average of $17.11 and a 200-day moving average of $12.39.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, analysts predict that Immunome will post -2.21 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.